-
News | 2015.01.13
Identification of an Achilles heel in the dengue virus gives new hope for vaccine development
Scientists have identified a vulnerable site on the surface of the dengue virus which is targeted by the only broadly neutralizing antibodies identified to date. This discovery offers a new target for the development of a vaccine to combat all four types of dengue virus currently in circulation.
-
News | 2024.12.20
Signing of a Memorandum of Understanding between the Institut Pasteur and the International Vaccine Institute (IVI)
The Institut Pasteur and the International Vaccine Institute (IVI) are strengthening their commitment to global health by signing a Memorandum of Understanding (MoU), marking a new milestone in their collaboration. The official ceremony took place on December 19, 2024, on the Institut Pasteur campus in Paris, in the presence of Yasmine Belkaid, Director General of the Institut Pasteur, and Dr....
-
News | 2023.04.28
Lassa fever: promising results for a vaccine candidate in a Phase I clinical trial
The Lassa arenavirus causes hemorrhagic fever and is a major problem in many West African countries, claiming 5,000 to 6,000 lives every year. There is therefore an urgent need to develop treatments and prepare for potential outbreaks. An international study involving Institut Pasteur researchers has reported the results of Phase I clinical trial for a Lassa fever vaccine. Vaccine candidates...
-
Document de presse | 2024.10.23
Pasteur Network members Unite Global Efforts to Accelerate mRNA Vaccine Research
PNAM2024: Pasteur Network members Unite Global Efforts to Accelerate mRNA Vaccine Research through Strategic Memorandum of UnderstandingRio de Janeiro, October 23rd, 2024 – Key members of the Pasteur Network, including Fundação Oswaldo Cruz (Fiocruz), the Institut Pasteur de Dakar, the Institut Pasteur Korea, the Institut Pasteur, and the Institut Pasteur de Tunis, have signed a strategic...
-
News | 2016.01.19
A yellow fever vaccines production facility, grant maintained by AFD, in Dakar
The French Development Agency (AFD) grants 6.5 million euros to the Institut Pasteur in Dakar Foundation. The financing agreement has been signed, on January 19, 2016 in Dakar, for the construction and equipment of an over 3000 m2 new yellow fever vaccine production facility.The event has taken place in the presence of His Excellency Jean-Félix- Paganon, French Ambassador to Senegal; Laurence...
-
News | 2025.06.11
The Institut Pasteur, Fiocruz and Sanofi establish strategic alliance for vaccine development
During the official visit of Brazilian President Luiz Inácio Lula da Silva to France, the Oswaldo Cruz Foundation (Fiocruz), the Institut Pasteur and Sanofi formed a strategic alliance aimed at fostering innovation and advance vaccine technologies. A Memorandum of Understanding (MoU) was signed on Thursday, June 5, laying the groundwork for scientific and technical cooperation in the field of...
-
News | 2021.01.20
A vaccine candidate based on glycochemistry targets shigellosis: promising Phase 1 results
Diarrheal diseases are the world's second leading cause of death in children aged under 5 years, and of these, bacillary dysentery or shigellosis remains a major public health issue. This disease is most prevalent in African and South-East Asian countries, where it is endemic despite significant improvements in terms of access to drinking water and management of contaminated water. Consequently,...
-
Document de presse | 2021.11.18
Covid-19: Systematic review of the clinical and immunological efficacy of vaccines in immunocompromised people
The team from the Cochin-Pasteur Clinical Investigation Center of Vaccinology at Cochin AP-HP Hospital, Inserm and the University of Paris, coordinated by Prof. Odile Launay, carried out a systematic review of the literature on immunogenicity and efficacy of Covid-19 vaccines in immunocompromised individuals. It concluded that there is a risk of low immunogenicity of Covid-19 vaccines among...
-
Document de presse | 2021.07.01
Modelling study of benefits and risks associated with the COVID-19 vaccine Vaxzevria
On April 7, 2021, the European Medical Agency (EMA) concluded that thrombosis in combination with thrombocytopenia has been identified as a likely adverse event following vaccination with the COVID-19 vaccine Vaxzevria. Researchers from the Mathematical Modelling of Infectious Diseases Unit at the Institut Pasteur used a mathematical model to assess its benefits and risks in...
-
News | 2019.09.27
Rabies: a shorter, cheaper vaccination schedule following a suspected rabid dog bite
A study by teams from the Institut Pasteur du Cambodge and the Institut Pasteur in Paris confirms the efficacy of the new post-exposure rabies vaccination schedule developed in the Institut Pasteur International Network and adopted by the World Health Organization (WHO). Since 2018, WHO has recommended post-exposure vaccination for rabies, immediately after a bite by a suspected rabid...